Symbiotec Pharmalab Q1 results, quarter to Jun 2026
NSE: SYMBIOTECBSE: 544889Pharmaceuticals & Biotechnology
Symbiotec Pharmalab Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2026 · Issue price ₹988
Last close ₹1,274.70down ₹3.10 (0.24%)BSE ₹1,274.00
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,277.80.
28 Oct: open ₹1,285.90, high ₹1,294.40, low ₹1,248.00
Range of traded prices from listing on 1 Sep 2026 to 28 Oct 2026
₹934.20Low, 1 Sep 2026₹1,309.90High, 16 Oct 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹8,191 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No balance sheet
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Sep 2026
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,50,41834.4% delivered
Symbiotec Pharmalab filed its Q1 results for the quarter to Jun 2026 on 21 Sep 2026 at 6:51 pm, consolidated: the company and its subsidiaries together.
Q1 results, quarter to Jun 2026
₹ crore.
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period. Revenue from operations in the glossary
- ₹218 Cr
- Operating profitOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax. Operating profit before depreciation (EBITDA) in the glossary
- ₹45 Cr
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax. Net profit in the glossary
- ₹14 Cr
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. Earnings per share in the glossary
- ₹2.24
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs. Operating margin in the glossary
- 20.7%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.4%
From revenue to net profit, ₹ crore
- Revenue218
- Materials and goods−76
- Employee costs−46
- Other expenses−51
- Operating profit45
- Depreciation−22
- Other income+0.3
- Finance costs−6.2
- Profit before tax18
- Tax−3.5
- Net profit14
Symbiotec Pharmalab results by quarter
Consolidated: the company and its subsidiaries together. Latest quarter to Jun 2026. Results for the quarter to Sep 2026 are due by 14 Nov 2026, 45 days after it ends. Every company's dates are on the results calendar.Results filings and date
| ₹ crore | Jun 2026Q1 |
|---|---|
| Revenue from operations | 218 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. Operating expenses in the glossary | 173 |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. Cost of materials and goods in the glossary | 76 |
| Employee costsEmployee costs. Salaries, wages, bonuses and other benefits paid to staff in the period. Employee costs in the glossary | 46 |
| Other expensesOther expenses. Every operating cost besides materials and staff: power, rent, freight, repairs, marketing and the like. Other expenses in the glossary | 51 |
| Operating profit before depreciation | 45 |
| Operating margin | 20.7% |
| Depreciation and amortisationDepreciation and amortisation. The part of the cost of plant, buildings and other long-lived assets charged against each year they are used. Depreciation and amortisation in the glossary | 22 |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. Other income in the glossary | 0 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. Finance costs in the glossary | 6 |
| One-off itemsExceptional items. Gains or losses the company reports separately because they are not expected to recur, such as selling a business or writing down an asset. Exceptional items in the glossary | 0 |
| Profit before tax | 18 |
| 3 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. Effective tax rate in the glossary | 19.8% |
| 14 | |
| Other comprehensive incomeOther comprehensive income. Gains and losses booked straight to net worth rather than through profit, such as changes in the value of some investments, pension plans and currency translation. Other comprehensive income in the glossary | 0 |
| Total comprehensive incomeTotal comprehensive income. Net profit plus other comprehensive income. Total comprehensive income in the glossary | 14 |
| Net margin | 6.4% |
| Earnings per share | ₹2.24 |
Earnings per share in rupees, restated for later splits and bonuses.